Last updated on April 2018

Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren


Brief description of study

The investigators will conduct a n=5,400 Phase 3, double-blind, individually randomised placebo-controlled clinical trial of 5 years' duration in primary schools in City of Cape Town Metropolitan Municipality, Western Cape Province, Republic of South Africa.

The primary objective of the trial is to determine whether a weekly oral dose of 0.25 mg (10,000 IU) vitamin D3, administered for three years, reduces risk of acquisition of latent tuberculosis infection (LTBI) in Cape Town primary schoolchildren.

Statistical analysis will be performed on an intention-to-treat basis to compare acquisition of LTBI in intervention vs. control arms during three-year follow-up. The primary analysis will be logistic regression with presence/absence of LTBI at follow-up as the outcome, adjusted for a random effect of school of attendance.

Clinical Study Identifier: NCT02880982

Contact Investigators or Research Sites near you

Start Over

Keren Middelkoop, MPH, PhD

Desmond Tutu HIV Foundation
Cape Town, South Africa
0.23miles
  Connect »